TNF Inhibitors Market Insights, 2018-2026

TNF Inhibitors Market (Drug - Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab; Application - Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

The rise in global occurrence of autoimmune illnesses such as Psoriasis, Inflammatory Bowel Disorder, Rheumatoid Arthritis (RA), and Crohn's disease, as well as the rise in the elderly populace, are the primary reasons likely to drive the expansion of the global TNF inhibitors market.

Golimumab, Etanercept, Certolizumab, Infliximab, and Adalimumab are TNF inhibitors utilized to address inflammatory illnesses such as inflammatory bowel disease and psoriasis. Manufacturers in the global TNF inhibitors market are likely to provide a wide range of medications to treat a variety of inflammatory illnesses. During the COVID-19 pandemic, however, a research found that if a patient was completely vaccinated with the Pfizer vaccine and was taking a TNF inhibitor, the patient's antibody response to the virus that caused COVID-19 was diminished. A third injection of the vaccine, according to the study, is likely to boost antibody levels in the body.

The global TNF inhibitors market is relatively competitive, with many prominent competitors. In terms of market share, a few major competitors currently dominate the industry. Some major players are purchasing other businesses in order to strengthen their global market positions, whilst others are developing new items. With the clearance of the US Food and Drug Administration (FDA) in December 2019, Amgen added another blockbuster medicine, AVSOLA (infliximab-axxq), to its current portfolio of biosimilar drugs. As of the reference product, Remicade (infliximab), the AVSOLA has been authorized for all indications of chronic inflammatory diseases, which is projected to boost the global TNF inhibitors market in the years to come.

tnf inhibitors market

Presence of Advanced Healthcare Facilities and Favorable Policies to Drive Demand in the Market

The world's population is aging rapidly, particularly in developed countries, such as the U.S., Japan, and Western Europe. In comparison to developing countries, developed countries have higher rate of aging. This can be linked to these nations' steadily growing health infrastructure, reimbursement systems, and advancements in health-care facilities. In addition to that, availability to numerous TNF inhibitors has increased, particularly in developed nations. As a result, the people's life expectancy has grown. The senior population is a big fan of TNF inhibitors since they help them live longer and better lives. An increase in the number of aged individuals leads to a higher risk of illness, which is anticipated to drive up demand in the global TNF inhibitors in the years to come.

High Prevalence of Rheumatoid Arthritis to Spell Growth for the Market

The US Food and Drug Administration authorized adalimumab, often known as Humira, as the first and only entirely human monoclonal antibody for the treatment of rheumatoid arthritis. Humira, AbbVie's largest medication, was released in 2003 and has consistently generated the most revenue for the firm, which is likely to fuel expansion of the global TNF inhibitors market in the years to come.

Due to its widespread prevalence, rheumatoid arthritis is likely to account for substantial chunk of the global TNF inhibitors market. Furthermore, rheumatoid arthritis is more common in women than in men, is predicted to account for around two-thirds of the entire patient population with arthritis, and it worsens with age, all of which are expected to move the global TNF inhibitors market forward.

Hospital pharmacies are predicted to acquire one of the leading market shares by owing to the availability of physicians and treatment in one single location. Additionally, biosimilars producers want to control the availability of their goods to as many hospitals and patients as possible in order to fulfill their increasing requirements, which is expected to fuel the segment's growth and contribute to its part of global market revenue.

Growing Prevalence of TNF Inhibitor Biosimilars is Expected to Support Market Expansion

Most of the major TNF inhibitors, such as remicade, Enbrel, and humira, have lost their patents in the recent years, and more TNF inhibitors are anticipated to lose their patents soon. As a result of patient affordability in low-income countries and increasing patient awareness, TNF inhibitor biosimilars are expected to acquire market share throughout the projection period. In 2016, the patent on humira (adalimumab), the world's most popular medication, expired. In 2014, Johnson & Johnson's remicade lost its patent. TNF inhibitor biosimilars are projected to open up profitable potential in low-income nations by making TNF inhibitors more accessible and inexpensive, which will likely increase TNF inhibitor usage. This, in turn, is expected to fuel the demand for TNF inhibitors. Furthermore, a robust clinical pipeline of TNF inhibitors biosimilars is anticipated to bolster growth of the global TNF inhibitors market.

North America and Europe to Lead the Market due to the Presence of Huge Ageing Population Base

North America is likely to lead the global TNF inhibitors market during the forecast period. The region's prominence is attributed to a number of factors, including well-established direct reimbursement regulations and the presence of superior healthcare infrastructure. Due to the USFDA's fast medication approval effort, which supported market expansion in this region, the US is likely to account for a substantial chunk of the market in the years to come.

Following North America, Europe is likely to account for the second-largest market for TNF inhibitors, driven by growing demand from the regional aging population and rising healthcare costs. Huge expenditures by leading players, as well as continued expansion in R&D efforts in the area, are likely to contribute significantly to market revenue during the forecast period.

Asia Pacific is expected to expand at a rapid growth rate, owing to the large patient populations in China and India for disorders including Crohn's disease, IBD, and psoriasis. Furthermore, an expansion in the role of the government in assisting the healthcare industry, as well as continuous research activities in the region, is likely to boost market growth in the region.

The global TNF inhibitors market is segmented as given below:

Drug

  • Adalimumab
  • Certolizumab
  • Etanercept
  • Golimumab
  • Infliximab

Application

  • Rheumatoid Arthritis
  • Psoriasis
  • Inflammatory Bowel Disease
  • Ankylosing Spondylitis
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America   
  • Middle East & Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the total market worth of TNF inhibitors market?

TNF inhibitors market to reach around US$ 53,745.37 Mn by 2026

What is the anticipated CAGR of the TNF inhibitors market in the forecast period?

TNF inhibitors market is anticipated to expand at a stable CAGR of 2.54% during the forecast period of 2018 to 2026

What are the key driving factors for the growth of the TNF inhibitors market?

TNF inhibitors market is driven by strong research & development and increasing awareness regarding usage of TNF inhibitors for the treatment of various rheumatic conditions

Which region is expected to project the highest market share in the global TNF inhibitors market?

North America is estimated to hold a leading share of the global TNF inhibitors market during the forecast period

Who are the key players in the global TNF inhibitors market?

Key players in the TNF inhibitors market include AbbVie, Inc., Janssen Biotech, Inc., UCB, Amgen, Inc., Pfizer, Inc., Samsung Bioepis, Biogen, Merck & Co., and Takeda Pharmaceutical Company

    1. Preface 
         1.1. Report Scope and Market Segmentation 
         1.2. Research Highlights

    2. Assumptions and Research Methodology      
         2.1. Assumptions and Acronyms Used
         2.2. Research Methodology

    3. Executive Summary
         3.1. Global TNF Inhibitors Market: Market Snapshot

    4. Market Overview
         4.1. Global TNF Inhibitors Market: Overview 
         4.2. Global TNF Inhibitors Market: Key Industry Developments
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
                4.3.4. Trends
         4.4. Global TNF Inhibitors Market Size (US$ Mn) Forecast, 2016–2026
         4.5. Global TNF Inhibitors Market Outlook
         4.6. Porter’s Five Forces Analysis
         4.7. Clinical trials pipeline analysis-TNF Inhibitors
         4.8. Overview of Regulatory Framework for Development and Approval of Biosimilars

    5. Global TNF Inhibitors Market Analysis, by Drug
         5.1. Key Findings
         5.2. Introduction
         5.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Drug
         5.4. Global TNF Inhibitors Market Value Forecast, by Drug
                5.4.1. Adalimumab
                5.4.2. Certolizumab
                5.4.3. Etanercept
                5.4.4. Golimumab
                5.4.5. Infliximab
         5.5. Global TNF Inhibitors Market Analysis, by Drug

    6. Global TNF Inhibitors Market Analysis, by Application
         6.1. Key Findings
         6.2. Introduction
         6.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Application
         6.4. Global TNF Inhibitors Market Value Forecast, by Application
                6.4.1. Rheumatoid Arthritis
                6.4.2. Psoriasis
                6.4.3. Inflammatory Bowel Disease
                6.4.4. Ankylosing Spondylitis
                6.4.5. Others 
         6.5. Global TNF Inhibitors Market Analysis, by Application

    7. Global TNF Inhibitors Market Analysis, by Distribution channel
         7.1. Key Findings
         7.2. Introduction
         7.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Distribution Channel
         7.4. Global TNF Inhibitors Market Value Forecast, by Distribution channel
                7.4.1. Hospital Pharmacy
                7.4.2. Retail Pharmacy
                7.4.3. Online Pharmacy
         7.5. Global TNF Inhibitors Market Analysis, by Distribution Channel

    8. Global TNF Inhibitors Market Analysis, by Region
         8.1. Global TNF Inhibitors Market Scenario, by Country
         8.2. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Region
         8.3. Global TNF Inhibitors Market Value Forecast, by Region
                8.3.1. North America
                8.3.2. Europe
                8.3.3. Asia Pacific 
                8.3.4. Latin America
                8.3.5. Middle East & Africa

    9. North America TNF Inhibitors Market Analysis and Forecast
         9.1. Key Findings
         9.2. North America TNF Inhibitors Market Overview
         9.3. North America TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country 
         9.4. North America TNF Inhibitors Market Forecast, by Country
                9.4.1. U.S.
                9.4.2. Canada
         9.5. North America TNF Inhibitors Market Value Share Analysis, by Drug
         9.6. North America TNF Inhibitors Market Forecast, by Drug
                9.6.1. Adalimumab
                9.6.2. Certolizumab
                9.6.3. Etanercept
                9.6.4. Golimumab
                9.6.5. Infliximab
         9.7. North America TNF Inhibitors Market Value Share Analysis, by Application
         9.8. North America TNF Inhibitors Market Forecast, by Application
                9.8.1. Rheumatoid Arthritis
                9.8.2. Psoriasis
                9.8.3. Inflammatory Bowel Disease
                9.8.4. Ankylosing Spondylitis
                9.8.5. Others 
         9.9. North America TNF Inhibitors Market Value Share Analysis, by Distribution channel
         9.10. North America TNF Inhibitors Market Forecast, by Distribution channel
                9.10.1. Hospital Pharmacy
                9.10.2. Retail Pharmacy
                9.10.3. Online Pharmacy
         9.11. North America TNF Inhibitors Market Attractiveness Analysis

    10. Europe TNF Inhibitors Market Analysis
         10.1. Key Findings
         10.2. Europe TNF Inhibitors Market Overview
         10.3. Europe TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
         10.4. Europe TNF Inhibitors Market Forecast, by Country
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Italy
                10.4.5. Spain
                10.4.6. Rest of Europe
         10.5. Europe TNF Inhibitors Market Value Share Analysis, by Drug 
         10.6. Europe TNF Inhibitors Market Forecast, by Drug
                10.6.1. Adalimumab
                10.6.2. Certolizumab
                10.6.3. Etanercept
                10.6.4. Golimumab
                10.6.5. Infliximab
         10.7. Europe TNF Inhibitors Market Value Share Analysis, by Application
         10.8. Europe TNF Inhibitors Market Forecast, by Application
                10.8.1. Rheumatoid Arthritis
                10.8.2. Psoriasis
                10.8.3. Inflammatory Bowel Disease
                10.8.4. Ankylosing Spondylitis
                10.8.5. Others
         10.9. Europe TNF Inhibitors Market Value Share Analysis, by Distribution channel
         10.10. Europe TNF Inhibitors Market Forecast, by Distribution channel
                10.10.1. Hospital Pharmacy
                10.10.2. Retail Pharmacy
                10.10.3. Online Pharmacy
         10.11. Europe TNF Inhibitors Market Attractiveness Analysis

    11. Asia Pacific TNF Inhibitors Market Analysis
         11.1. Key Findings
         11.2. Asia Pacific TNF Inhibitors Market Overview
         11.3. Asia Pacific TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
         11.4. Asia Pacific TNF Inhibitors Market Forecast, by Country
                11.4.1. China
                11.4.2. India
                11.4.3. Japan
                11.4.4. Australia & New Zealand
                11.4.5. Rest of Asia Pacific
         11.5. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Drug
         11.6. Asia Pacific TNF Inhibitors Market Forecast, by Drug
                11.6.1. Adalimumab
                11.6.2. Certolizumab
                11.6.3. Etanercept
                11.6.4. Golimumab
                11.6.5. Infliximab
         11.7. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Application
         11.8. Asia Pacific TNF Inhibitors Market Forecast, by Application
                11.8.1. Rheumatoid Arthritis
                11.8.2. Psoriasis
                11.8.3. Inflammatory Bowel Disease
                11.8.4. Ankylosing Spondylitis
                11.8.5. Others
         11.9. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Distribution channel
         11.10. Asia Pacific TNF Inhibitors Market Forecast, by Distribution channel
                11.10.1. Hospital Pharmacy
                11.10.2. Retail Pharmacy
                11.10.3. Online Pharmacy
         11.11. Asia Pacific TNF Inhibitors Market Attractiveness Analysis

    12. Latin America TNF Inhibitors Market Analysis
         12.1. Key Findings
         12.2. Latin America TNF Inhibitors Market Overview
         12.3. Latin America TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
         12.4. Latin America TNF Inhibitors Market Forecast, by Country
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of Latin America
         12.5. Latin America TNF Inhibitors Market Value Share Analysis, by Drug
         12.6. Latin America TNF Inhibitors Market Forecast, by Drug
                12.6.1. Adalimumab
                12.6.2. Certolizumab
                12.6.3. Etanercept
                12.6.4. Golimumab
                12.6.5. Infliximab
         12.7. Latin America TNF Inhibitors Market Value Share Analysis, by Application
         12.8. Latin America TNF Inhibitors Market Forecast, by Application
                12.8.1. Rheumatoid Arthritis
                12.8.2. Psoriasis
                12.8.3. Inflammatory Bowel Disease
                12.8.4. Ankylosing Spondylitis
                12.8.5. Others
         12.9. Latin America TNF Inhibitors Market Value Share Analysis, by Distribution channel
         12.10. Latin America TNF Inhibitors Market Forecast, by Distribution channel
                12.10.1. Hospital Pharmacy
                12.10.2. Retail Pharmacy
                12.10.3. Online Pharmacy
         12.11. Latin America TNF Inhibitors Market Attractiveness Analysis

    13. Middle East & Africa TNF Inhibitors Market Analysis
         13.1. Key Findings
         13.2. Middle East & Africa TNF Inhibitors Market Overview
         13.3. Middle East & Africa TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
         13.4. Middle East & Africa TNF Inhibitors Market Forecast, by Country
                13.4.1. South Africa
                13.4.2. UAE
                13.4.3. Saudi Arabia
                13.4.4. Rest of Middle East and Africa
         13.5. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Drug
         13.6. Middle East & Africa TNF Inhibitors Market Forecast, by Drug
                13.6.1. Adalimumab
                13.6.2. Certolizumab
                13.6.3. Etanercept
                13.6.4. Golimumab
                13.6.5. Infliximab
         13.7. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Application
         13.8. Middle East & Africa TNF Inhibitors Market Forecast, by Application
                13.8.1. Rheumatoid Arthritis
                13.8.2. Psoriasis
                13.8.3. Inflammatory Bowel Disease
                13.8.4. Ankylosing Spondylitis
                13.8.5. Others 
         13.9. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Distribution channel
         13.10. Middle East & Africa TNF Inhibitors Market Forecast, by Distribution channel
                13.10.1. Hospital Pharmacy
                13.10.2. Retail Pharmacy
                13.10.3. Online Pharmacy
         13.11. Middle East & Africa TNF Inhibitors Market Attractiveness Analysis

    14. Competitive Landscape
         14.1. Company Profiles
                14.1.1. AbbVie, Inc.
                         14.1.1.1.1. Company Details
                         14.1.1.1.2. Business Overview
                         14.1.1.1.3. Financial Overview
                         14.1.1.1.4. Strategic Overview
                         14.1.1.1.5. SWOT Analysis
                14.1.2. Janssen Biotech, Inc.
                         14.1.2.1.1. Company Details
                         14.1.2.1.2. Business Overview
                         14.1.2.1.3. Financial Overview
                         14.1.2.1.4. Strategic Overview
                         14.1.2.1.5. SWOT Analysis
                14.1.3. Amgen, Inc.
                         14.1.3.1.1. Company Details
                         14.1.3.1.2. Business Overview
                         14.1.3.1.3. Financial Overview
                         14.1.3.1.4. Strategic Overview
                         14.1.3.1.5. SWOT Analysis
                14.1.4. UCB Inc.
                         14.1.4.1.1. Company Details
                         14.1.4.1.2. Business Overview
                         14.1.4.1.3. Financial Overview
                         14.1.4.1.4. Strategic Overview
                         14.1.4.1.5. SWOT Analysis
                14.1.5. Samsung Bioepis
                         14.1.5.1.1. Company Details
                         14.1.5.1.2. Business Overview
                         14.1.5.1.3. Financial Overview
                         14.1.5.1.4. Strategic Overview
                         14.1.5.1.5. SWOT Analysis
                14.1.6. Biogen
                         14.1.6.1.1. Company Details
                         14.1.6.1.2. Business Overview
                         14.1.6.1.3. Financial Overview
                         14.1.6.1.4. Strategic Overview
                         14.1.6.1.5. SWOT Analysis
                14.1.7. Merck & Co.
                         14.1.7.1.1. Company Details
                         14.1.7.1.2. Business Overview
                         14.1.7.1.3. Financial Overview
                         14.1.7.1.4. Strategic Overview
                         14.1.7.1.5. SWOT Analysis
                14.1.8. Takeda Pharmaceutical Company
                         14.1.8.1.1. Company Details
                         14.1.8.1.2. Business Overview
                         14.1.8.1.3. Financial Overview
                         14.1.8.1.4. Strategic Overview
                         14.1.8.1.5. SWOT Analysis
                14.1.9. Pfizer, Inc.
                         14.1.9.1.1. Company Details
                         14.1.9.1.2. Business Overview
                         14.1.9.1.3. Financial Overview
                         14.1.9.1.4. Strategic Overview
                         14.1.9.1.5. SWOT Analysis

    List of Tables

    Table 01: Opportunity Map, by Drug
    Table 02: Opportunity Map, by Application
    Table 03: Opportunity Map, Distribution Channel
    Table 04: Global TNF Inhibitors Market Size (US$ Mn) Forecast, by Drug, 2016–2026
    Table 05: Global TNF Inhibitors Market Size (US$ Mn) Forecast, by Application, 2016–2026
    Table 06: Global TNF Inhibitors Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 07: Global TNF Inhibitors Market Size (US$ Mn) Forecast, by Region, 2016–2026
    Table 08: North America TNF Inhibitors Market Size (US$ Mn) Forecast, by Country, 2016–2026
    Table 09: North America TNF Inhibitors Market Size (US$ Mn) Forecast, by Drug, 2016–2026
    Table 10: North America TNF Inhibitors Market Size (US$ Mn) Forecast, by Application, 2016–2026
    Table 11: North America TNF Inhibitors Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 12: Europe TNF Inhibitors Market Size (US$ Mn) Forecast, by Country/Region, 2016–2026
    Table 13: Europe TNF Inhibitors Market Size (US$ Mn) Forecast, by Drug, 2016–2026
    Table 14: Europe TNF Inhibitors Market Size (US$ Mn) Forecast, by Application, 2016–2026
    Table 15: Europe TNF Inhibitors Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 16: Asia Pacific TNF Inhibitors Market Size (US$ Mn) Forecast, by Country/Region, 2016–2026
    Table 17: Asia Pacific TNF Inhibitors Market Size (US$ Mn) Forecast, by Drug, 2016–2026
    Table 18: Asia Pacific TNF Inhibitors Market Size (US$ Mn) Forecast, by Application, 2016–2026
    Table 19: Asia Pacific TNF Inhibitors Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 20: Latin America TNF Inhibitors Market Size (US$ Mn) Forecast, by Country/Region, 2016–2026
    Table 21: Latin America TNF Inhibitors Market Size (US$ Mn) Forecast, by Drug, 2016–2026
    Table 22: Latin America TNF Inhibitors Market Size (US$ Mn) Forecast, by Application, 2016–2026
    Table 23: Latin America TNF Inhibitors Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 24: Middle East & Africa TNF Inhibitors Market Size (US$ Mn) Forecast, by Country/Region, 2016–2026
    Table 25: Middle East & Africa TNF Inhibitors Market Size (US$ Mn) Forecast, by Drug, 2016–2026
    Table 26: Middle East & Africa TNF Inhibitors Market Size (US$ Mn) Forecast, by Application, 2016–2026
    Table 27: Middle East & Africa TNF Inhibitors Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    Figure 01: Global TNF Inhibitors Market Size (US$ Mn), by Drug 2017 (A)
    Figure 02: Global TNF Inhibitors Market Revenue (%), by Application, 2017 
    Figure 03: Global TNF Inhibitors Market Size (US$ Mn) Forecast, 2016–2026
    Figure 05: Market Value Share, by Drug (2017)
    Figure 07: Market Value Share, by Distribution Channel (2017)
    Figure 04: Market Value Share, by Region (2017)
    Figure 06: Market Value Share, by Application (2017)
    Figure 08: Global TNF Inhibitors Market Value Share Analysis, by Drug, 2016 and 2026
    Figure 09: Global TNF inhibitors Market Attractiveness, by Drug, 2018–2026
    Figure 10: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Adalimumab, 2016–2026
    Figure 11: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Certolizumab, 2016–2026
    Figure 12: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Etanercept, 2016–2026
    Figure 13: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Golimumab, 2016–2026
    Figure 14: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Infliximab, 2016–2026
    Figure 15: Global TNF Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
    Figure 16: Global TNF Inhibitors Market Attractiveness, by Application, 2018–2026
    Figure 17: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Rheumatoid Arthritis, 2016–2026
    Figure 18: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Psoriasis, 2016–2026
    Figure 19: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Inflammatory Bowel Disease,    2016–2026
    Figure 20: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Ankylosing Spondylitis, 2016–2026
    Figure 21: Global TNF Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
    Figure 22: Global TNF Inhibitors Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 23: Global TNF Inhibitors Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 24: Global TNF Inhibitors Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacy, 2016–2026
    Figure 25: Global TNF Inhibitors Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacy, 2016–2026
    Figure 26: Global TNF Inhibitors Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacy, 2016-2026
    Figure 27: Global TNF Inhibitors Market Value Share, by Region, 2016 and 2025 
    Figure 28: Global TNF Inhibitors Market Attractiveness, by Region, 2018–2026
    Figure 29: North America TNF Inhibitors Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 30: North America TNF Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
    Figure 31: North America TNF Inhibitors Market Attractiveness Analysis, by Country, 2018–2026
    Figure 32: North America TNF Inhibitors Market Value Share Analysis, by Drug, 2017 and 2026
    Figure 33: North America TNF Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
    Figure 34: North America TNF Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and       2026
    Figure 35: North America TNF Inhibitors Market Attractiveness Analysis, by Drug, 2018–2026
    Figure 36: North America TNF Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
    Figure 37: North America TNF Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 38: Europe TNF Inhibitors Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 39: Europe TNF Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
    Figure 40: Europe TNF Inhibitors Market Attractiveness Analysis, by Country, 2018-2026
    Figure 41: Europe TNF Inhibitors Market Value Share Analysis, by Drug, 2017 and 2026
    Figure 42: Europe TNF Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
    Figure 43: Europe TNF Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 44: Europe TNF Inhibitors Market Attractiveness Analysis, by Drug, 2018–2026
    Figure 45: Europe TNF Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
    Figure 46: Europe TNF Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 47: Asia Pacific TNF Inhibitors Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
    Figure 48: Asia Pacific TNF Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
    Figure 49: Asia Pacific TNF Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018?2026
    Figure 50: Asia Pacific TNF Inhibitors Market Value Share Analysis, by Drug, 2017 and 2026
    Figure 51: Asia Pacific TNF Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
    Figure 52: Asia Pacific TNF Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 53: Asia Pacific TNF Inhibitors Market Attractiveness Analysis, by Drug, 2018–2026
    Figure 54: Asia Pacific TNF Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
    Figure 55: Asia Pacific TNF Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 56: Latin America TNF Inhibitors Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
    Figure 57: Latin America TNF Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
    Figure 58: Latin America TNF Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018?2026
    Figure 59: Latin America TNF Inhibitors Market Value Share Analysis, by Drug, 2017 and 2026
    Figure 60: Latin America TNF Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
    Figure 61: Latin America TNF Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and   2026
    Figure 62: Latin America TNF Inhibitors Market Attractiveness Analysis, by Drug, 2018–2026
    Figure 63: Latin America TNF Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
    Figure 64: Latin America TNF Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 65: Middle East & Africa TNF Inhibitors Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018– 2026
    Figure 66: Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 67: Middle East & Africa TNF Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018?2026
    Figure 68: Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Drug, 2017 and 2026
    Figure 69: Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
    Figure 70: Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 71: Middle East & Africa TNF Inhibitors Market Attractiveness Analysis, by Drug, 2018–2026
    Figure 72: Middle East & Africa TNF Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
    Figure 73: Middle East & Africa TNF Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 74: Global TNF Inhibitors Market Share Analysis, by Company (2017)

Copyright © Transparency Market Research, Inc. All Rights reserved